Abstract 4307
Background
Predictors of pCR to neoadjuvant chemotherapy (NAC) for breast cancers have been studied extensively. We focused on CR to antracycline-based chemotherapy using MRI for prediction of pCR, in patients treated with NAC with anthracycline and taxane-based regimens.
Methods
Tumor measurements were done at diagnosis, after anthracyclines and at the end of taxanes. pCR was defined as absence of residual invasive foci and no lymph nodeinvolvement. Associations of clinicopathologic parameters with pCR were evaluated with the χ2 test. All test results with a p value of less than 0.05 were considered significant.
Results
A total of 114 TNBC patients were treated with NAC. Median age was 53 (28-77) years. 44 patients (38.6%)had stage II and 67(58.8%)stage III. Mutation in BRCA was detected in 9 patients and variants of uncertain significance in 5. 49 patients (43%) with tumor size by MRI > 50 mm, 49 (43%) with positive results on fine needle aspiration of axilla (FNAA), and 88 (77.2%) with histologic grade III. NAC regimen consisted in 108 patients (94.7%) of 4 cycles of epirrubicin+cyclophosphamide (CP) and in 3 patients (2.6%) 4 cycles of doxorubicin+CP, followed by taxane-based regimens. 43 patients (37.7%) had pCR. CR by MRI occurred in 22 patients (19.3%) after anthracycline-based regimen. At the end of NAC there were 37 patients (32.5%) with CR by MRI. Association of clinicopathologic parameters with pCR were: 62.8% pCR in patients with tumor size ≤ 50mm (p = 0.389); 58.1% in patients with FNAA + (p = 0.238); 81.4% in grade III tumors (p = 0.700); 46.5% pCR in patients with CR by MRI after anthracycline-based regimen (p = 0.0001) and 65.1% pCR in patients with CR by MRI before surgery (p = 0.0001). All the patients with CR by MRI after anthracycline-based regimen had a CR by MRI before surgery.
Conclusions
CR by MRI after treatment with anthracyclines could be a clinically useful predictor of pCR in patients with TBNC treated preoperatively with anthracylcines and taxane-based regimens and patients who not reach CR after anthraclines could benefit from improve taxans regimen.
Clinical trial identification
Legal entity responsible for the study
Luis Antonio Fernandez Morales.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract